National Cancer Institute (NCI)
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, National Cancer Institute (NCI) sits in the top decile of US sponsors by registered trial count (#1 of 15,751 sponsors by registered trial count).
National Cancer Institute (NCI): 3,257 sponsored US clinical trials, 326 recruiting.
National Cancer Institute (NCI) sponsors 3,257 registered US clinical trials on ClinicalTrials.gov, 326 of them currently recruiting, and 2,051 completed. 193 of these trials are in Phase 3-4 (later-stage) and 2,628 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Advanced Malignant Solid Neoplasm, with 67 trials.
Top-decile sponsor footprint
National Cancer Institute (NCI) ranks in the top decile of sponsors by registered trial count (#1 of 15,751 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Open and recent trials
3,257 total, page 56 of 66
Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction
NCT00025415
BMS-275291 in Treating Patients With HIV-Related Kaposi's Sarcoma
NCT00024024
EF5 to Evaluate Tumor Hypoxia in Patients With High-Grade Soft Tissue Sarcoma or Mouth Cancer
NCT00896961
BMS-247550 in Treating Patients With Liver or Gallbladder Cancer
NCT00023946
R115777 to Treat Children With Neurofibromatosis Type 1 and Progressive Plexiform Neurofibromas
NCT00021541
SU6668 in Treating Patients With Advanced Solid Tumors
NCT00024206
Interleukin-12 in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer
NCT00016289
BMS-214662 Plus Trastuzumab in Treating Patients With Advanced Solid Tumors
NCT00022529
Chemotherapy With or Without Trastuzumab in Treating Patients With Metastatic Osteosarcoma
NCT00023998
Gefitinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer
NCT00024089
Bevacizumab, Fluorouracil, and Hydroxyurea Plus Radiation Therapy in Treating Patients With Advanced Head and Neck Cancer
NCT00023959
Thalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
NCT00022581
PS-341 in Treating Patients With Metastatic Malignant Melanoma
NCT00024011
Hepatic Arterial Infusion With Melphalan in Treating Patients With Unresectable Liver Cancer
NCT00030082
Long-Term Survival With HIV: Psychological and Behavioral Factors Associated With the Transition From Adolescence to Young Adulthood
NCT00026806
Use of EF5 to Measure the Oxygen Level in Tumor Cells of Patients Undergoing Surgery or Biopsy for Newly Diagnosed Supratentorial Malignant Glioma
NCT00430079
Bevacizumab, Idarubicin, and Cytarabine in Treating Patients With Blast Phase Chronic Myelogenous Leukemia
NCT00023920
Interferon Alfa Plus Thalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
NCT00015912
Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma That Has Not Responded to Previous Treatment
NCT00022438
Ixabepilone in Treating Patients With Advanced Urinary Tract Cancer
NCT00021099
Combination Chemotherapy Plus Bevacizumab in Treating Patients With Metastatic Prostate Cancer
NCT00016107
Bortezomib in Treating Patients With Lymphoproliferative Disorders
NCT00023764
Combination Chemotherapy and Radiation Therapy With or Without Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery
NCT00020709
Combination Chemotherapy Followed By Donor Bone Marrow or Umbilical Cord Blood Transplant in Treating Children With Newly Diagnosed Juvenile Myelomonocytic Leukemia
NCT00025038
BMS-247550 in Treating Patients With Advanced Soft Tissue Sarcoma
NCT00022542
Study of Plexiform Neurofibromas in Neurofibromatosis Type 1
NCT00006435
Bevacizumab to Treat Inflammatory Breast Cancer or Locally Advanced Breast Cancer
NCT00016549
Vaccine Therapy in Treating Patients With Metastatic Cancer
NCT00021164
STI571 Plus Cytarabine in Treating Patients With Chronic Myelogenous Leukemia
NCT00015834
Combination Chemotherapy in Treating Patients With Advanced Cancer
NCT00021073
EMD 121974 in Treating Patients With Advanced Solid Tumors
NCT00022113
CCI-779 in Treating Patients With Recurrent Glioblastoma Multiforme
NCT00016328
Bortezomib in Treating Patients With Recurrent Glioma
NCT00006773
Combination Chemotherapy, Surgery, and Radiation Therapy With or Without Dexrazoxane and Trastuzumab in Treating Women With Stage III or Stage IV Breast Cancer
NCT00016276
Imatinib Mesylate With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed or Recurrent Glioma
NCT00021229
The Second Multicenter Hemophilia Cohort Study
NCT00341705
Assessment of Blood Vessel Density in Kaposi's Sarcoma Lesions
NCT00026793
Surveillance of Fungal Infections in Bone Marrow/Stem Cell and Organ Transplant Recipients
NCT00026767
Monoclonal Antibody Therapy and Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma
NCT00017381
Flavopiridol in Treating Children With Relapsed or Refractory Solid Tumors or Lymphomas
NCT00012181
Monoclonal Antibody Therapy in Treating Patients With Chronic Lymphocytic Leukemia, Lymphocytic Lymphoma, Acute Lymphoblastic Leukemia, or Acute Myeloid Leukemia
NCT00017472
S0108 Bevacizumab in Treating Patients With Non-Hodgkin's Lymphoma
NCT00016094
Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
NCT00016302
Thalidomide in Treating Patients With Myelodysplastic Syndrome
NCT00015990
Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer Previously Treated With Irinotecan
NCT00016978
Combination Chemotherapy Plus Oblimersen in Treating Patients With Previously Untreated Extensive-Stage Small Cell Lung Cancer
NCT00017251
Radiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and Interleukin-11 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
NCT00012298
Pilot Study of Non-Myeloablative, HLA-Matched Allogeneic Stem Cell Transplantation for Pediatric Hematopoietic Malignancies
NCT00013533
Depsipeptide to Treat Patients With Cutaneous T-Cell Lymphoma and Peripheral T-Cell Lymphoma
NCT00007345
Chemotherapy Plus Sargramostim in Treating Patients With Refractory Myeloid Cancer
NCT00012376
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1199 |
| Phase 2 | 1429 |
| Phase 3 | 193 |
Therapeutic Areas
What is open in the National Cancer Institute (NCI) pipeline
326 recruiting of 3,257 indexed (10% open); 2,051 completed (63%).
Phase mix: 193 late (III/IV) vs 2,628 early (I/II) (early-phase heavy).
Top condition: Advanced Malignant Solid Neoplasm (67 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.